Sotagliflozin SCORED favourably in patients with T2D, CKD
25 Jan 2021
byAudrey Abella
Use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor sotagliflozin led to a reduction in the risk of deaths from cardiovascular (CV) causes, hospitalizations for heart failure (HF), and urgent visits for HF compared with placebo among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) regardless of the degree of albuminuria, the SCORED* trial has shown.